3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Classical hematology
1
Conditions
Colorectal Neoplasms
24
Neoplasms
12
Colonic Neoplasms
12
Breast Neoplasms
12
Prostatic Neoplasms
9
Polycythemia Vera
9
Venous Thromboembolism
8
Multiple Myeloma
8
Recurrence
5
Rectal Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Thrombocythemia, Essential
4
Ovarian Neoplasms
4
Neoplasms, Plasma Cell
4
Neoplasm Metastasis
4
Myeloproliferative Disorders
4
Barrett Esophagus
4
Precancerous Conditions
3
Melanoma
3
Esophageal Neoplasms
3
Adenomatous Polyps
3
Adenoma
3
Tobacco Use Disorder
2
Thrombosis
2
Thromboembolism
2
Smoking Cessation
2
Sarcoma
2
Primary Myelofibrosis
2
Neoplastic Cells, Circulating
2
Neoplasms by Site
2
Interventions
Cisplatin
13
Etoposide
11
Paclitaxel
8
Cyclophosphamide
7
Carboplatin
7
Ifosfamide
6
etoposide phosphate
5
Granulocyte Colony-Stimulating Factor
5
Gemcitabine
5
pembrolizumab
4
fludarabine
4
Sirolimus
4
Bleomycin
4
fludarabine phosphate
3
Sunitinib
3
Oxaliplatin
3
Mesna
3
Melphalan
3
Filgrastim
3
Drug Therapy
3
Brentuximab Vedotin
3
Bevacizumab
3
Automobiles
3
130-nm albumin-bound paclitaxel
3
tremelimumab
2
sodium thiosulfate
2
ribociclib
2
pralsetinib
2
pegfilgrastim
2
durvalumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Neoplasms, Germ Cell and Embryonal
×
Aspirin
×
Clear all
NCT06866964
2026-02-02
ASPIRE
Wake Forest University Health Sciences
Phase 2
Recruiting
35 enrolled